Pharma BD Deal Intelligence
AstraZeneca to acquire TeneoTwo and T-cell engager TNB-486 for $100M upfront plus up to $1.17B milestones.
AstraZeneca acquired TeneoTwo with lead asset TNB-486 for $100M upfront and up to $1.165B in milestones.
AstraZeneca to acquire TeneoTwo in deal worth up to $1.26 billion for clinical T-cell engager.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AstraZeneca acquired TeneoTwo in October 2022 (closed 17 Oct 2022) for $100M upfront plus up to $1.165B in milestones (total up to ~$1.265B), gaining the Phase 1 CD19xCD3 bispecific T-cell engager TNB-486 for relapsed/refractory B-cell malignancies. Post-close the asset has advanced markedly: it received the INN surovatamig (AZD0486) and AstraZeneca moved it directly from Phase 1 into two Phase 3 pivotal programs. SOUNDTRACK-F1 (NCT06549595, Phase III, recruiting, started Aug 2024) tests surovatamig plus rituximab versus chemoimmunotherapy plus rituximab in previously untreated follicular lymphoma; a second Phase 3 (SOUNDTRACK-D2) evaluates surovatamig with R-mini-CHOP in large B-cell lymphoma. Phase 1 follicular-lymphoma data (ASH 2024) showed a 96% overall response rate and 85% complete response at doses >=2.4 mg with predominantly low-grade cytokine release syndrome, and R/R DLBCL data (ASCO/ASH 2025) showed high MRD-negative complete responses including after prior CD20 TCE and CD19 CAR-T. The deal thesis has strengthened: AstraZeneca's bispecific bet is now a late-stage, potentially first-in-class CD19xCD3 program in B-cell lymphoma.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / TeneoTwo Inc. (this deal) | 2022 | $1.3B | 62 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2022 deals · AstraZeneca PLC deals · Oncology deals